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I would like to begin with a brief
historical review of the subject of
insulin antigenicity before I discuss
its clinical significance.
After the discovery of insulin, a
little over four decades ago, some
of the early preparations of insulin
were relatively crude; and, as might
be expected, a number of reactions
occurred. In one of the first studies
on insulin allergy utilizing pure
crystalline insulin, Tuft ( 1928)
established that it was the insulin
itself which caused the skin reaction and not the protein of the
animal from which the insulin
came. He further demonstrated
that the material causing the skin
reaction could be passively transferred to the skin of a normal
individual by an intradermal injection of serum from the insulinallergic individual. He also showed
the presence of a precipitin against
insulin in the serum of the insulinallergic patient and demonstrated
that the skin-sensitizing antibody
remained in serum long after the
precipitin was lost. He presented
some evidence of an increased insulin requirement in the patient
when the precipitin was present
and suggested that antibodies to
insulin might be associated with
insulin resistance. Other workers
confirmed the fact that insulin was
antigenic (Prout, 1962) and Sir
Frederick Banting (1938) made the
observation that psychiatric patients receiving insulin for shock
therapy required more and more
insulin to produce shock as time
went on. He demonstrated that
serum from these patients protected mice from convulsions when
injected with insulin and later
showed that the anti-insulin mateMCV QUARTERLY 2(1): 19-23, 1966

rial was located in the serum globulin rather than the albumin.
In 1944 Lowell defined the two
kinds of antibodies against insulin,
one a reagin which was heat labile
and caused skin sensitization, and
the other a heat-stable factor that
prevented the hypoglycemic effect
of insulin in vivo.
Loveless and Cann (1955)
showed that the heat-stable precipitin, the material with antiinsulin effect in the intact animal,
could in fact act as a blocking antibody for the skin-sensitizing reagin
or the heat labile factor. These antibodies traveled in two distinct areas
on serum electrophoresis; the blocking antibody was a y-globulin, while
the skin-sensitizing reagin traveled
with the ft-globulins.
Up to this time insulin was
thought to be rarely associated with
host reactions except for the occasional local reaction to injection.
It was Berson and his associates
(1956) who showed that insulin
antigenicity was a common phenomenon. In patients who have
been treated with intermediate or
long-acting insulin, 80% have antibodies in the serum that are measureable by techniques utilizing insulin labelled with iodine 131
(table 1) .
Most of the clinical manifestations of the skin-sensitizing reagin
are straightforward. Some of the
rarer forms of sensitivity reaction
attributable to insulin are difficult
to substantiate (e.g. thrombocytopenia and gastrointestinal upset),
but the skin reactions to insulin
are not at all unusual. It is quite
common to have local reactions to
insulin in the first few weeks after
insulin injections are started. In
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TABLE l
Insulin Antigenicity

Tuft (1928)

Skin Sensitivity

Insu Ii n Resistance

Passive cutaneous
transfer

Precipitin in serum
Mouse protection by
globulin of insulinresistant patient

Banting (1938)

Lowell (1944)

Heat-labile

Heat stable. Reioted to resistance.
Possibly species
specific

Loveless and
Cann (1955)

Separated with
13 -globulin

Separated with ')' globulin. "Blocking
antibody"

Berson (1956)

Insulin-binding
antibody

TABLE 2
Saturation in Insulin-binding Antibodies*

% Retention in Serum
60 min

% Free Serum Insulin
5 min

45 u/day

83

2. l

90 u/day

72

3.3

190 u/day

48

17.6

Daily
Insulin

*The relationship between dailh dose of insulin and saturation of
insulin-binding antibodies is s own by these results. Free insulin
is increased and becomes availqble for peripheral use. The increase in daily insulin does not stimulate the over-production of
antibodies in this type of patient.
'
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treating the patient with local reactions, it is essential to be certain
that the patient is injecting himself
properly, that he is using a clean
syringe and not injecting alcohol.
Some physicians advocate that
syringes and sites of injection be
changed or that the insulin be
warmed or even boiled; after several weeks in which several techniques have been tried, the local reactions subside. I suspect that this
is not related to the ingenuity of
the therapeutic maneuvers, but to
time that has been consumed while
waiting for the blocking antibodies
to block the skin-sensitizing antibody. The patient has been desensitized in precisely the same
way that he has been desensitized
for ragweed antigen, and the important part of therapy has been
the continuation of injections until
the patient is desensitized.
Other phenomena at the injection site are of great interest although it is not provi;!n that they
are related to insulin antigenicity.
These are the insulin-induced fat
atrophy and/ or fat hypertrophy.
Their cause remains an enigma. I
have wondered whether insulin may
become fixed to adipose tissue at
the injection site and set up a tissuefixed antigen-antibody reaction with
circulating antibodies. The time
sequence suggests the validity of
this possibility and on occasions a
change to insulin of a different
species has coincided with the end
to fat atrophy. I am currently trying to improve these demonstrations and determine their significance. These phenomena may well
relate to the effect of insulin on fat
metabolism, but thus far the reasons for both fat atrophy and fat
hypertrophy are obscure.
The clinical significance of the
heat-stable antibody to insulin
found in the y-globulin is more
easily determined. If we study the
insulin-binding capacity of the
serum of patients attending a diabetes clinic, we find that all patients
taking intermediate insulin develop
antibodies in six to eight weeks.
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In general the titre of antibodies is
low, and as a group the patients
who have been on insulin the longest period of time have the higher
titres. There is, of course, great
variability. There are several interesting exceptions to this generalization. Insulin antibodies have been
noted to disappear in patients receiving steroid for sarcoidosis. In
other patients having the proteinuria of Kimmelstiel-Wilson syndrome, insulin-binding antibodies
are often lost along with other proteins. Part of the insulin sensitivity
seen in patients with this syndrome
is probably related to the loss with
the proteinuria of the buffering
effect of the antibodies. In such patients the antibody titre seen in the
serum is low even through the patient had been on insulin for more
than 20 years.
As Berson ( 1956) demonstrated,
the presence of antibodies is readily
shown in vivo. In patients with
little or no antibody, there is rapid
disappearance from the blood of insulin labelled with 1''11 following an
intravenous injection. Patients with
insulin resistance show a marked
prolongation of the half-time of
labelled insulin in blood, and it is
easy to show that the insulin J'31
continues to circulate because it is
bound to the y-globulin.
Let me give an illustration of the
clinical significance of this. A man
previously controlled on 40 units
of insulin developed ketoacidosis
without obvious cause. He was
treated successfully and discharged
on his previous dose of 40 units
daily. In a short time he returned
again with ketoacidosis. An insulin
effect had been obtained and the
acidosis had been treated successfully, but this effect was promptly
dissipated when he returned to his
maintenance dose that was less than
his daily needs. It was postulated
that by saturating the circulating
antibodies with larger daily doses
of insulin the anti-insulin effect of
his antibodies could be neutralized.
It was first demonstrated that approximately 90 % of the injected

insulin J'31 remained in circulation
for more than two hours while he
was on an inadequate dose of insulin. We then progressively raised
his insulin dose, and he began to
come under better control. Now
we found that injected insulin 1'31
disappeared from the blood more
quickly, presumably because some
of the binding sites of the insulinbinding antibody were being occupied by the daily dose of insulin
he was receiving. As his insulin ·
dose was increased during the next
week, he showed progressive shortening of the half-time of insulin in
his blood and reciprocally a greater
amount of the insulin was free to
be utilized in the periphery. Insulin
bound to antibody is preserved not
only from peripheral use but also
from peripheral degradation. The
results of these studies of insulin1'31 over this period are shown in
table 2. As the increased daily dose
of insulin occupied more of the
binding sites of the insulin-binding
globulin, more of the daily insulin
dose was free to exert its physiological effects, and the control of
his diabetes was thereby improved
(Prout and Katims, 1959).
Insulin resistance is not always
related to insulin-binding antibodies, of course, and in the differential diagnosis of this problem a
number of other conditions must
be considered (table 3). Obesity is
usually associated with relative insulin resistance. Obese patients who
have never received insulin may
require three or four times as much
insulin to produce the same fall in
blood glucose on an insulin tolerance test as their colleagues of
normal weight. Obese diabetic subjects who have not followed their
prescribed diet and who hence are
not controlled may require 50 to
60 units daily at the onset to
achieve control, although they are
not dependent on insulin to prevent
ketoacidosis.
Moderate degrees of insulin resistance are seen in acromegaly,
Cushing's syndrome, hyperthyroidism, and with steroid treatment.
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Cyclic resistance associated with the
menstrual cycle has been reported.
None of these states are related to
antibodies and are all relatively
mild forms of resistance for the
most part.
Infection, of course, is the most
common cause of insulin resistance
and resistance quickly disappears
as the infection is brought under
control. Although an increase in
insulin-binding antibodies with infection would appear likely, we
have not found a significant rise
in circulating antibodies of any of
these patients' studies, the most
remarkable of whom has been reported by Knowles and his colleagues (see Tucker et al., 1964) .
Peripheral or tissue resistance to
the effects of insulin has been postulated and there are remarkable
instances reported of severe resistance on this basis that are unrelated to insulin antibodies (Field,
1962). Another cause of apparent
insulin resistance is the so-called
Somogyi effect or paradoxical hyperglycemia (Somogyi, 1959). This
refers to the patient who appears
to need more insulin but in whom
control becomes more difficult despite the increase in his insulin
dose. Hypoglycemia that often goes
undetected is followed by rebound
hyperglycemia and the patient and
the physician are likely to increase
the dose further unless the paradoxical hyperglycemia is recognized. The proper treatment is to
decrease rather than increase the
insulin dose after which the apparent insulin resistance disappears.
Evidence that the antibodies are
not the result of high insulin dosage
used in insulin resistance rather
than a cause is difficult to find. I
had an opportunity to study one
patient who has helped to answer
this question. A woman had had
diabetes for a number of years and
had developed insulin resistance
with requirements of insulin exceeding 1,500 units per day. Her
physician had told her that insulin
was useless for her and the patient
had discontinued her injections.
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When seen, she had been off all
treatment for four years. During
this time, she had had constant
glycosuria and had developed severe peripheral neuropathy. We
measured her insulin-binding capacity after four years on no insulin
and found an insignificant amount
of binding still present, about 50
microunits per ml. We began insulin in relatively low doses and
at the dose of 60 units of insulin
per day, an insulin effect was seen.
Her urine became free of glucose
for the first time in four years. On
the eighth day after beginning therapy she was again found to be
extremely resistant to insulin and
impossible to control; her insulinbinding antibodies had increased
ten fold. An attempt was made
immediately to saturate the high
level of circulating antibodies by
giving her 500 units of insulin intravenously which, under these specific circumstances, was quite safe
and no effect of this insulin was
seen on the blood glucose. Insulins
from different species were tried as
well as steroids ; but in spite of
this, on insulin in doses up to 1,500
units daily, she did not respond.
After oral agents became available,
hyperglycemia was controlled to
some degree. This patient was found
responsive to insulin in moderate
doses before the recurrence of insulin resistance. Antibodies developed before massive doses of insulin were used and resistance
became clinically significant with
the rapid rise of antibodies.
What steps do we take when confronted with an insulin-resistant patient? Let us assume that the obvious causes of insulin resistance,
such as obesity or infection, have
been ruled out and that the insulin
requirements are in excess of 200
units per day. First we should
determine whether the patient is
really insulin dependent. The two
phenomena do not necessarily go
hand in hand. Insulin dependency
is related to the presence or absence of retrievable insulin from
the pancreas. Insulin resistance is

related to response to injected
insulin and may develop in patients
still capable of responding to oral
agents. The patient just described
illustrates this. If the patient is not
insulin dependent, an oral hypoglycemic agent may be effective. If
this fails, and insulin therapy is
mandatory, one may attempt to
saturate the antibodies by rapidly
increasing the insulin dose as I
have described above. This can
sometimes be best accomplished by
using crystalline insulin in multiple
doses throughout the day; this is
always more effective in patients
with a large amount of insulinbinding antibody than is intermediate or long-acting insulin. If this
does not succeed, insulin from different species, usually pork insulin,
can be tried.

TABLE 3
Differential Diagnosis of Insulin Resistance

I) Obesity

Relative resistance easily

2) Endoc rine states:
a ) acromegaly

Mild resistance. Usually

b) Cushing's syndrome

less than 100 units/ day

c ) hyperthyroidism
d) menstrual cycle

of insulin required unless

3) Peri pheral resistanc e

other complications ore
present.
Unusual condition difficult to prove . Very high
quantities of insulin used

with little effec t.
4) Infection

Commonest form of re-

sistanc e, Rapidly reversed with treatment of

infection .
5) A ntibodies to insulin

De monstration by in v ivo
or in vitro techniques.

TABLE 4
Treatment of Insulin Resistance Related to
Insulin-binding Antibodies
l) Determine insulin dependency
2) Antibody saturation
3) Change to insulin of another species
(pork, f ish)
4) Adrenal steroids or ACTH
5) Anti-metabolites not recommended
6) Time and continued treatment with
insulin in crystalline form
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Antimetabolites such as 6-mercaptopurine theoretically might
help these patients by suppressing
formation of antibodies. This has
been tried on several occasions
without any great success (Merimee, 1965).
Adrenal steroids are relatively
low on the treatment list for insulin resistance. It is better to have
a patient maintained on 300 units
of insulin a day than to have him
on steroids for life. Steroids can
sometimes be used to decrease
insulin resistance but the resistance
frequently returns when steroids
are tapered and stopped, and longterm steroid treatment may be required. Steroids must be used, as
elsewhere in medicine, with circumspection.
Not the least important in the
treatment of insulin resistance due
to insulin binding antibodies is the
use of time. If the resistant patient
can be maintained on a high dose
of insulin required for control,
eventually the resistance may disappear in the same way it came,
indeed, with less explanation. Continuation of insulin, especially as
crystalline or regular insulin, is
essential in such patients (table 4).
Interruption of insulin therapy may
in fact be one of the settings in
which relative insulin resistance
occurs when insulin is restarted.
Thus we have seen that evidence
of insulin antigenicity in one or
more forms is present in most individuals receiving intermediate insulins for six weeks or longer. A
number of clinical manifestations
of insulin antigenicity and their
treatment have been discussed.
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